Mana.bio key facts
as of Oct 2026- Operator of an artificial intelligence-based drug delivery company intended to facilitate lipid nanoparticle development for oligonucleotide therapies.
- Mana.bio is valued at approximately $30.8M as of Oct 2026 (last reported valuation).
- It has raised $19.5M; the latest was Seed Round in Sep 2025.
- Notable investors include Andreessen Horowitz, Gaingels, NFX, Base4 Capital, LionBird — 7 tracked in total.
- Status: Privately Held (backing).
Mana.bio's last reported valuation, Oct 2023. Nothing priced has surfaced since.
- ·Watch Mana.bio: the Monday email on marks, rounds and moves
Mana.bio funding rounds
No funding rounds for Mana.bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Mana.bio valuation
Mana.bio's last reported valuation was $30.8 million in Oct 2023. No priced round, secondary trade or fund mark has surfaced since.
Mana.bio investors
7 investors are on record for Mana.bio, including Andreessen Horowitz, Gaingels, NFX and Base4 Capital.
About Mana.bio
Operator of an artificial intelligence-based drug delivery company intended to facilitate lipid nanoparticle development for oligonucleotide therapies. The company uses technology powered by the integration of machine learning and nanotechnology to identify formulations of lipid nanoparticle systems and focus on gene therapy, including DNA and RNA-based therapeutics, and vaccines, enabling the healthcare industry to get a better drug delivery service.
- Sector
- Healthcare
- HQ
- Tel Aviv, Israel
- Founded
- 2021
- Employees
- 20
- Website
- mana.bio/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.